Immortal Time Bias and Issues in Critical Care. Dave Glidden May 24, 2007

Similar documents
Regression Output: Table 5 (Random Effects OLS) Random-effects GLS regression Number of obs = 1806 Group variable (i): subject Number of groups = 70

Age (continuous) Gender (0=Male, 1=Female) SES (1=Low, 2=Medium, 3=High) Prior Victimization (0= Not Victimized, 1=Victimized)

Generalized Mixed Linear Models Practical 2

THIS TALK STATINS REDUCE: Immortal time bias Immeasurable time bias Time-window bias TIME-RELATED BIASES IN PHARMACOEPIDEMIOLOGY

Sarwar Islam Mozumder 1, Mark J Rutherford 1 & Paul C Lambert 1, Stata London Users Group Meeting

Outcomes: Initially, our primary definitions of pneumonia was severe pneumonia, where the subject was hospitalized

Least likely observations in regression models for categorical outcomes

Joseph W Hogan Brown University & AMPATH February 16, 2010

Name: emergency please discuss this with the exam proctor. 6. Vanderbilt s academic honor code applies.

Overview. All-cause mortality for males with colon cancer and Finnish population. Relative survival

Daniel Boduszek University of Huddersfield

Finland and Sweden and UK GP-HOSP datasets

appstats26.notebook April 17, 2015

ECON Introductory Econometrics Seminar 7

Bias and confounding special issues. Outline for evaluation of bias

Matched Cohort designs.

Notes for laboratory session 2

BIOSTATISTICAL METHODS

GSK Medicine: salmeterol, Salmeterol+Fluticasone proprionate, fluticasone propionate, beclomethasone

The SAS SUBTYPE Macro

ADVANCED STATISTICAL METHODS: PART 1: INTRODUCTION TO PROPENSITY SCORES IN STATA. Learning objectives:

Sociology Exam 3 Answer Key [Draft] May 9, 201 3

BIOSTATISTICAL METHODS AND RESEARCH DESIGNS. Xihong Lin Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA

Online Supplementary Material

Journal of Physics: Conference Series. Related content PAPER OPEN ACCESS

Statistics as a Tool. A set of tools for collecting, organizing, presenting and analyzing numerical facts or observations.

Regression Methods in Biostatistics: Linear, Logistic, Survival, and Repeated Measures Models, 2nd Ed.

Year in Review: Critical Care Medicine

Landmarking, immortal time bias and. Dynamic prediction

Jae Jin An, Ph.D. Michael B. Nichol, Ph.D.

m 11 m.1 > m 12 m.2 risk for smokers risk for nonsmokers

Polmoniti: Steroidi sì, no, quando. Alfredo Chetta Clinica Pneumologica Università degli Studi di Parma

PubH 7405: REGRESSION ANALYSIS. Propensity Score

Multivariable Cox regression. Day 3: multivariable Cox regression. Presentation of results. The statistical methods section

The Statistical Analysis of Failure Time Data

1. Objective: analyzing CD4 counts data using GEE marginal model and random effects model. Demonstrate the analysis using SAS and STATA.

We have no disclosures

TITLE: A Data-Driven Approach to Patient Risk Stratification for Acute Respiratory Distress Syndrome (ARDS)

Supplementary Online Content

ENDPOINTS FOR AKI STUDIES

Steroids in ARDS: if, when, how much? John Fowler, MD, FACEP Dept. of Emergency Medicine Kent Hospital, İzmir, Türkiye

CHL 5225 H Advanced Statistical Methods for Clinical Trials. CHL 5225 H The Language of Clinical Trials

HIV risk associated with injection drug use in Houston, Texas 2009: A Latent Class Analysis

Editor Executive Editor Associate Editors Copyright Statement:

By: Mei-Jie Zhang, Ph.D.

G , G , G MHRN

COMPARISON OF THE SURVIVAL OF SHIPPED AND LOCALLY TRANSPLANTED CADAVERIC RENAL ALLOGRAFTS

Project Cohort EXPOSED GROUP

Critical illness- A new co-morbidity?

Design and Analysis Plan Quantitative Synthesis of Federally-Funded Teen Pregnancy Prevention Programs HHS Contract #HHSP I 5/2/2016

LONGITUDINAL TREATMENT PATTERNS AND ASSOCIATED OUTCOMES IN PATIENTS WITH NEWLY DIAGNOSED SYSTEMIC LUPUS ERYTHEMATOSUS. Hong Kan 7/12/2016

Methodology for Non-Randomized Clinical Trials: Propensity Score Analysis Dan Conroy, Ph.D., inventiv Health, Burlington, MA

Fundamental Clinical Trial Design

Self-controlled case-series method

Changing Patterns in Medication Use with Increasing Probability of Death for Older Medicare Beneficiaries

SUPPLEMENTARY DATA. Supplementary Figure S1. Cohort definition flow chart.

Up-to-date survival estimates from prognostic models using temporal recalibration

Propensity Score Methods to Adjust for Bias in Observational Data SAS HEALTH USERS GROUP APRIL 6, 2018

Final Exam - section 2. Thursday, December hours, 30 minutes

Cross-validation. Miguel Angel Luque Fernandez Faculty of Epidemiology and Population Health Department of Non-communicable Diseases.

Antidepressant Use and Depressive Symptoms in Intensive Care Unit Survivors

Instrumental Variables I (cont.)

Applied Medical. Statistics Using SAS. Geoff Der. Brian S. Everitt. CRC Press. Taylor Si Francis Croup. Taylor & Francis Croup, an informa business

Canadian Trauma Trials Collaborative. Occult Pneumothorax in Critical Care (OPTICC): Standardized Data Collection Sheet

Reflection Questions for Math 58B

Trials. Paul Carpenter, MB.BS. Associate Member, FHCRC Associate Professor, UW. Novartis: Nilotinib for relapse prophylaxis after HCT

Stratified Tables. Example: Effect of seat belt use on accident fatality

Ovarian cancer example: h(t rx, age) = h(t) exp(β1 rx + β2 age) > cph1 = coxph(surv(futime, fustat)~rx+age, ovarian) > summary(cph1)

Selected Topics in Biostatistics Seminar Series. Missing Data. Sponsored by: Center For Clinical Investigation and Cleveland CTSC

Benchmark Dose Modeling Cancer Models. Allen Davis, MSPH Jeff Gift, Ph.D. Jay Zhao, Ph.D. National Center for Environmental Assessment, U.S.

Cross-validated AUC in Stata: CVAUROC

Measures of Association

A Novel Score to Estimate the Risk of Pneumonia After Cardiac Surgery

Making comparisons. Previous sessions looked at how to describe a single group of subjects However, we are often interested in comparing two groups

Statistical Methods in Medical Research

4. STATA output of the analysis

Supplementary Appendix

Our goal in this section is to explain a few more concepts about experiments. Don t be concerned with the details.

Contingency Tables Summer 2017 Summer Institutes 187

Analysis of TB prevalence surveys

Treatment Strategy for Non-curative Resection of Early Gastric Cancer. Jun Haneg Lee. Sungkyunkwan University, Samsung Medical Center, Seoul Korea

Time-varying confounding and marginal structural model

National COPD Audit Programme

Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database

Modeling unobserved heterogeneity in Stata

Cover Page. The handle holds various files of this Leiden University dissertation

CHAMP STUDY SIMULATIONS: PICK THE WINNER. Elizabeth Zahn 19 May 2014

Fitting discrete-data regression models in social science

Name: BIOS 703 MIDTERM EXAMINATIONS (5 marks per question, total = 100 marks)

Statistical reports Regression, 2010

Analysis of Environmental Data Conceptual Foundations: En viro n m e n tal Data

Comparison between Logistic and Calibration Linear Regression

OHDSI Tutorial: Design and implementation of a comparative cohort study in observational healthcare data

The impact of metoprolol on insulin sensitivity in the ICU

Facilitating EndotracheaL Intubation by Laryngoscopy technique and Apneic Oxygenation Within the Intensive Care Unit (FELLOW)

Section A: Clarification on effectiveness data. Licensed population

Supplementary Online Content

PREDICTORS OF PROLONGED HOSPITAL STAY

Pitfalls to Avoid in Observational Studies in the ICU

Zhao Y Y et al. Ann Intern Med 2012;156:

Transcription:

Immortal Time Bias and Issues in Critical Care Dave Glidden May 24, 2007

Critical Care Acute Respiratory Distress Syndrome Patients on ventilator Patients may recover or die Outcome: Ventilation/Death

ARDS Example Ventilated Off Ventilation Dead

Ventilator-Free Days Count days off ventilator (until day 28) ventilator-free days (VFD) For subjects who die, VF days set to 0 Two-group: Mann-Whitney U-test Approach designed for clinical trial

Data Example Collaboration with ICU investigators Cohort of ventilated patients Red blood cell transfusion (RBC) Does it increase time on the ventilator? Does it increase risk of death? RBC given over clinical course in ICU

Simplistic Example Consider 12 ventilated patients RBC occurs at 10 or 20 days into ICU Do RBC patients have longer stay An example of immortal time bias

12 Ventilated ICU Patients 0 5 10 15 20 25 30 Days in ICU

RBC Transfusions at 10 or 20 days 0 5 10 15 20 25 30 Days in ICU

RBC Transfusions at 10 or 20 days Subjects Randomly Selected for Transfusion x x x x 0 5 10 15 20 25 30 Days in ICU

Transfused Subjects Mean ICU Stay: 19 days 0 5 10 15 20 25 30 Days in ICU

Non VAP subjects Mean ICU Stay: 16 days 0 5 10 15 20 25 30 Days in ICU

Exposed Time 0 5 10 15 20 25 30 Days in ICU

Mean Residual Stay (Non Transfused): 9 days Mean Residual Stay (Transfused): 9 days 0 5 10 15 20 25 30 Days in ICU

Mean Residual Stay (Non Transfused): 5 days Mean Residual Stay (Transfused): 5 days 0 5 10 15 20 25 30 Days in ICU

Example Patients ever exposed to RBC vented longer Transfused patients: two kinds of vent time Time before Trx: longer than non-trx the so-called immortal time Time after trans: same as Trans- subjects Should time before Trans count for Trans+?

Other Examples PTLD increase risk of death in kidney tx? Do OSCAR winners live longer? Does heart tx extend life in listed patients? Common thread: exposure occurs sometime after follow-up PTLD, transplants, awards occur over time

Immortal Time Bias Recent study Statin subjects develop BCC after starting statins: FU time before statins is immortal Adds time to statin+ group How can we handle this? Will underestimate BCC rate in statin

Steroids in COPD A more subtle example Cohort patients discharged after COPDrelated illness Exposure: inhaled corticosteroids (ICS) That 90 days leads to the bias Outcome: death or hospitalization in 1 yr Exposed if filled ICS prescription in 90 days

Two Classic Approaches Matching Regression

Matching Identifies cases of BCC Case #156: BCC at 6 years, no statins Has matched control(s) Cont. #156-1: BCC- at 6 years, 2 years statin use (years 8-10) Control is unexposed! Only count statin exposure up to year 6 Fair: don t count statin exposure after BCC

Careful Matching Matched controls can become cases Control for case #156 selected at random from those with no BCC after 8 years Choosing from no BCC after 10 years induces slight bias If disease is rare, bias is negligible

Analysis Matched design requires matched analysis Conditional logistic regression (binary) Stratified Cox model (time-to-event) Makes comparisons within pairs only

Time Dependent Covariates A time-dependent covariate is a predictor whose values may vary with time...and measured during the study

Regression Approach Creates exposure variable: 1: statins 0: no statins Acknowledges that exposure changes Time prior to exposure, statin=0 Time after exposure: statin=1 Time-dependent covariate!

Time dependent covariate Treat statin as a time-dependent covariate statin = { 0 before initiating statins 1 after initiating statins risk = { baseline risk before statins RR*baseline risk after statins two groups but membership changes

Two patients Case #156: BCC at 6 years, no statins Cont. #156-1: BCC- at 10 years, 2 years statin use (years 8-10) Can code as time-dependent covariates

Data +------------------------------------+ idno t_from t_to statin bcc ------------------------------------ 219. 156 0 6 0 1 200. 156-1 0 8 0 0 221. 156-1 8 10 1 0 +------------------------------------+ idno: indicates subjects t_from: start of interval t_to: end of interval statin: statins in interval bcc: bcc in interval 27

Time-Dependent Covs Can be incorporated into Cox regression Use all the FU data doesn t discard FU just for matching Takes duration into account Some delicate modeling issues Doesn t work for all outcomes e.g., ventilator free days

Bad News Survival of OSCAR winners reanalysis show 1 year survival advantage not significant Inhaled steroids in COPD extensively studied and debated appears advantage due to immortal time Suissa (2007) documents 20 studies with this possible bias

TD Covs in Vent-Free Days X i: Number of Ventilator-Free Days Δi: Alive at 28 days (1=yes, 0=no) VDF = XiΔi Model 1: pr(δi = 1) Model 2: f(xi Δi = 1)

Model #1 Cox model for survival Predictors entered as TD Covs Builds a model for pr(δi = 1) = pr( survive to 28 days)

Survival Time Cox regression -- Breslow method for ties No. of subjects = 973 Number of obs = 6530 No. of failures = 81 Time at risk = 6530 LR chi2(1) = 5.32 Log likelihood = -541.89494 Prob > chi2 = 0.0210 ------------------------------------------------------------------------------ _t Haz. Ratio Std. Err. z P> z [95% Conf. Interval] -------------+---------------------------------------------------------------- prbc 2.153839.6572039 2.51 0.012 1.184363 3.916892 ------------------------------------------------------------------------------

Model #2 Ventilator-Free Days Repeated events among survivors Each day off vent is repeated event Model rate of new days off ventilator

Time on Ventilator No. of subjects = 720 Number of obs = 4974 No. of failures = 972 Time at risk = 4974 Wald chi2(1) = 25.32 Log pseudolikelihood = -6023.2217 Prob > chi2 = 0.0000 (Std. Err. adjusted for 720 clusters in patno) ------------------------------------------------------------------------------ Robust _t Haz. Ratio Std. Err. z P> z [95% Conf. Interval] -------------+---------------------------------------------------------------- prbc.2844534.071075-5.03 0.000.1743112.4641911 ------------------------------------------------------------------------------

Model for VFD E( VFD Z) = pr( Δ=1 Z) E(X Δ=1,Z) First part from model 1 Second term from model 2 Other combinations are possible as well

Results Possible to model td cov but requires survival analysis methods Even in the absence of censoring Survival analysis keep track of time carefully essential for avoid immortal time bias